Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 April 2022 | Story Elsabé Brits
Andre Roodt and Alice Brink
Prof Andreas Roodt and Prof Alice Brink are two of the inventors of the ‘Multinuclear complexes and their preparation patent.

According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six. The most common cancers are breast, lung, colon, rectum, and prostate cancers. There is a constant need to provide methods to diagnose and treat cancer-related tumours.  Current research strategies focus on eliminating cancer cells with the minimum damage to surrounding healthy cells.

A limitation of current technologies is that they are mostly based on the separate identification of cancer (diagnostic), followed by treatment (therapy) using chemotherapy and/or radiotherapy. To fit both needs at the same time and with similar or identical compounds, the principle of theranostic medicine was identified. This concept employs both diagnosing (by imaging) cancer and delivering therapy (treatment) simultaneously, which has been receiving increased attention internationally.

Collaborating with the University of Zurich
A University of the Free State (UFS) team, together with a team from the University of Zürich, conducted exciting research in this area and filed a patent titled ‘Multinuclear complexes and their preparation’. The patent was granted in South Africa and by the European Patent Office. It is being validated in selected European countries. The patent is pending in the USA, Japan, Hong Kong, and India. The inventors from the UFS are Prof Andreas Roodt, Prof Alice Brink, Dr Pennie Mokolokolo, and Dr Vincent Dumisani Kama. The approach that their technology takes is to enable the synthesis of a multinuclear compound/s, which may contain different pre-selected radioisotopes, to allow both imaging and therapy to the cancer site(s) with one and the same metal-organic complex.

So far, high-yield production of compounds has been successfully innovated, which contain both an imaging (in particular the widely utilised imaging isotope Technetium-99m) and therapeutic (typically the therapeutic isotope Rhenium-186) radioactive isotope(s), optionally carrying an additional cytotoxic agent. (Chemotherapy uses anti-cancer [cytotoxic] drugs to destroy cancer cells.)

Nuclear medicine technologies
In the next phase of the research, a lead compound portfolio of four to five model pharmaceuticals containing these metal nuclides with appropriate directing groups to target cancer sites will be designed and constructed. A number of these entities are known and can be introduced through different techniques. These will then undergo full characterisation and efficacy evaluation in biological models (in vitro), followed by extensive animal and human trials.

The technology will be delivered as a product or service in the way that current nuclear medicine technologies are delivered.

The fact that this product(s) contains both imaging and therapeutic radionuclides or cytotoxic modalities, enables detailed tracking of the pharmaceutical and monitoring of the tumours' response to the therapy. Not directly related to the patent, but an asset to it, is the fact that the incorporation of rhenium with a high atomic number (Z = 75) opens the additional opportunity to utilise the multinuclear compounds also as radiosensitisers. Synergistic effects, enhancing the therapeutic efficacy, can thus be expected in combination with radiotherapy.

The UFS would like to partner with a pharmaceutical company working in the field of nuclear medicine to commercialise this technology. Interested parties can contact Ravini Moodley at MoodleyR5@ufs.ac.za

News Archive

Because you can do the undoable
2014-05-30


Gabriela Schroder

Since visiting the University of Vermont in 2011 as an F1 student and attending the Stanford Sophomore College the year after, Gabriela Schroder has never stopped dreaming and working towards her objectives.

During the autumn graduation earlier in 2014, Gabriela received the Dean’s Medal. This award goes to the final-year student who achieves the best results in respect of a first Bachelor’s degree in the Faculty of Natural and Agricultural Sciences. Her triumph did not end there. In addition, she also received the Senate’s Medal and Prize which is awarded to the best Bachelor’s degree student at the university. Across all the faculties of our university. 

“Although these medals came to me as a surprise, it really was a reward to my hard work and toil throughout my undergraduate years,” she said. Schroder was also honoured and introduced by Prof Jonathan Jansen on stage at this year’s Kovsie Open Day, along with other top achieving students. She believes that anybody can reach their goals if they are willing to make sacrifices and through focus, hard work and determination. 

One of her favourite quotes that motives her is of Albert Einstein, “You really understand something if you can explain it to your grandmother.” In the process of learning, one must break down what they are working towards. She advises to make the knowledge your own – this develops a better insight into the concept. In the end, that which is regarded as complex is originally built from simple principles.

Schroder is currently studying towards her BSc Honours in Biochemistry at Kovsies. She has her sights set on a master’s degree in the near future.

“To my fellow Kovsies and beyond: seize your opportunities. Don’t be afraid to think the unthinkable – because you can do the undoable,” she added.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept